SecBot SecBot
Biotech Drug Report Generated Nov 14, 2026

KSI-101

KOD·Kodiak Sciences Inc.
BULLISH
Drug Impact Rating7/10
Trial phase
Phase 3
Time to market
If Phase 3 PEAK succeeds, a BLA submission would follow. The company expects Pivotal Analysis 2 data in Q2 2027, suggesting a potential BLA filing in 2027 and potential approval in 2028, though no official timeline has been given.
Why 7/10
The next hard, dated catalyst is the topline data from Pivotal Analysis 1 of the Phase 3 PEAK trial (300-patient cohort, 24-week primary endpoint), expected in December 2026, roughly one month from today. KSI-101 is a major pipeline asset at Kodiak but not the sole value driver (the company also has Zenkuda (heading for BLA submission) and KOD) and KSI-501 (Phase 3 ALTO for DME), so the score is 7 rather than 8-10.
Actionable Insight BULLISH

The December 2026 PEAK topline data is the key binary event to watch. If KSI-101 replicates the Phase 1b APEX signal (meaningful vision gains, rapid retinal drying) in the larger Phase 3 setting, it would validate the bispecific IL-6/VEGF approach and strengthen Kodiak's pipeline beyond Zenkuda. A miss or underwhelming result would be a significant negative given the elevated stock price and stretched cash position. The company's thin equity base ($12.6 million) and ~$66 million quarterly burn rate mean financing risk is high regardless of the readout outcome.

Price Chart

Loading chart...

How It Works

KSI-101 is a bispecific protein drug injected into the eye that simultaneously blocks two disease pathways: IL-6 (a driver of inflammation) and VEGF (a driver of abnormal blood vessel growth and leakage). By targeting both pathways at once, it aims to treat macular edema (fluid buildup in the retina) caused by inflammatory conditions like uveitis, which standard anti-VEGF-only drugs may not fully address.

Trial Status

KSI-101 is in a global Phase 3 program consisting of two pivotal trials: PEAK (single cohort of 300 patients) and PINNACLE. The first 300-patient cohort in PEAK completed enrollment in August 2026, with topline data from the 24-week primary endpoint expected in December 2026 (Pivotal Analysis 1). A second 600-patient cohort across both PEAK and PINNACLE is also enrolling, with data expected in Q2 2027 (Pivotal Analysis 2). Prior Phase 1b APEX study data showed meaningful vision gains as early as week 4, with over 90% of patients achieving absence of macular edema and effects sustained through week 20 weeks after a single dose.

The Two-Sided Case

▲ Bull Case6
Phase 1b APEX data showed strong results: meaningful vision gains as early as week 4, over 90% of patients achieving absence of macular edema, and more than half of patients in top dose levels gaining 15+ letters (3 lines) on the eye chart after a single dose (source: Kodiak press release, September 2025)
The company's platform and retinal disease expertise were validated by the September 2026 DAYBREAK Phase 3 success for Zenkuda and KSI-501, which de-risks the broader pipeline including KSI-101 (source: Kodiak 8-K filed November 12, 2026)
Baker Bros. Advisors, a 10% owner and director, made large open-market purchases of roughly $24 million in early November 2026 at ~$98.51/share, signaling insider confidence ahead of the December readout
Strong institutional accumulation in Q3 2026: FMR LLC added 58%, JPMorgan added 86%, Franklin Templeton added 93%, and multiple other funds added or doubled positions
Analyst consensus is strongly bullish: 7 Buy, 2 Strong Buy, 2 Hold, 0 Sell; mean price target $129.83 implying ~20% upside from $108.25
JP Morgan upgraded KOD in February 2026 specifically citing KSI-101 as derisked by APEX data (source: MSN news, February 2026)
▼ Bear Case5
Cash burn is severe: Q3 2026 net loss was $66.2 million, and cash dropped to $88.7 million at quarter-end (plus $69 million raised post-quarter via ATM). Stockholders' equity was only $12.6 million, raising going-concern risk if additional financing is not secured (source: Kodiak 10-Q filed November 12, 2026, and 8-K analysis)
The stock already trades at a ~$6.8 billion market cap after the 178% DAYBREAK surge, embedding optimistic assumptions. A Seeking Alpha analyst (November 13, 2026) argues the valuation already prices in Zenkuda success and that more financing is likely (source: Seeking Alpha, November 13, 2026)
Competition is emerging: Genentech/Roche is developing vamikibart for uveitic macular edema, with positive Phase III MEERKAT and SANDCAT data presented in October 2026 (source: Genentech press release via marketscreener, October 2026)
The CFO John Borgeson sold shares in late October 2026 (though under a 10b5-1 plan), totaling roughly $747,000 in sales
MESI is a relatively niche indication compared to wet AMD or diabetic macular edema, limiting peak revenue potential even if approved

Upcoming Catalysts

  • December 2026: Topline data from Phase 3 PEAK Pivotal Analysis 1 topline results (300 patients, 24-week primary endpoint)
  • Q2 2027: Pivotal Analysis 2 data from combined PEAK and PINNACLE cohorts (600 patients)
  • Q4 2026: Multi-indication BLA submission for Zenkuda (separate program, but relevant for company sentiment)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Kodiak Sciences Inc. 8-K KOD ·Originating report

Sources · 9

Hover a chip for the title
1 morningstar.com2 msn.com3 wtnh.com4 nasdaq.com5 napavalleyregister.com6 seekingalpha.com7 sec.gov8 sec.gov9 streetinsider.com